Poland· PL-100345865
Sumigra 100
A sumatriptan product containing sumatriptanum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Sumatriptan is registered in 17 of 19 countries.
Countries holding a registration under ATC N02CC01 (sumatriptan), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Sumatriptan · ATC N02CC01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sumatriptan costs, country by country.
Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.13 in United States to $2.70 in Switzerland — a ×21 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Sumatriptan · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- CH Switzerland$2.70
- IT Italy$0.71
- FR France$0.59
- US United States$0.13 (acquisition cost)
The record
At a glance
URPL (Poland)- Active substance
- Sumatriptanum
- Manufacturer
- InPharm Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- N02CC01
- ATC class
- Sumatriptan
- Defined daily dose
- 20 mg, N
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909991225841
- gtin05909991225858
- gtin05909991225865
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
147 interactions on record for sumatriptan.
Graded by severity as the source publishes them — 13 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sumatriptan · interactions on record
147 records
- 13 severe
- 4 moderate
- 129 info
Most severe, free to view
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
- PalonosetronA04AA05severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N02CC01
Sumatriptan, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e58fac92-55ad-428c-a1f4-f530365f9aef GET /v1/drugs/e58fac92-55ad-428c-a1f4-f530365f9aef?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "100 mg",
"packaging": "05909991225841 ¦ Rp ¦ 108903\n2 tabl.\n05909991225858 ¦ Rp ¦ 108904\n6 tabl.\n05909991225865 ¦ Rp ¦ 108905\n12 tabl.",
"substance": "Sumatriptanum 100 mg",
"common_name": "Sumatriptanum",
"pl_product_id": "100345865",
"pozwolenie_nr": "327/15",
"auth_procedure": "IR",
"authorisation_validity": "2025-06-12"
}See everything about sumatriptan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.